



About Vertex Pharmaceuticals



Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people living with serious diseases, with a focus on specialty markets.

Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, we have research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East.

Research & Development Strategy

We invest in diseases where there is a significant unmet need and we can have a transformative impact for patients, not just an incremental benefit. We invest the majority of our resources in research and development (R&D) to discover new medicines, because we believe the true value in our industry is unleashed through scientific innovation.

A disease-first company

We work only on diseases where we have a deep understanding of the underlying cause in humans. By focusing on validated targets, creating predictive lab assays, and identifying clinical biomarkers, we pursue therapeutic approaches that we believe are most likely to succeed.

Our differentiated approach

Our R&D strategy is unique and differentiates us in the industry. When we decide to work on a disease, we investigate it from multiple angles and invent, acquire or partner on the tool or technology necessary. We are agnostic to therapeutic modality and see modality as a means to transform, if not potentially cure, a disease.

OUR APPROACHES INCLUDE:

-  Small molecules
-  Cell therapies
-  Gene editing
-  mRNA therapies



Reshma Kewalramani, M.D., FASN
CEO and President

A blueprint for serial innovation

Vertex has a track record of serial innovation. We discovered, developed and produced the first medicines to target the underlying cause of cystic fibrosis. And we're pioneering various approaches using innovative tools and technologies — like CRISPR/Cas9, encapsulated cell



Vertex Pharmaceuticals Incorporated

Quick Facts

Founded:

1989

CEO and President:

Reshma Kewalramani, M.D., FASN

Employees:

>5,000 worldwide (>4,300 in the U.S.)

Corporate Headquarters:

50 Northern Avenue
Boston, MA 02210
Tel. +1 617-341-4100

International Headquarters:

2 Kingdom Street
London, W2 6BD
United Kingdom
Tel. +44 2032-045100

Research Sites:

Boston area; Providence, R.I.;
San Diego; Oxford, U.K.

therapies and more — that have the potential to have a transformative impact for patients who are waiting.

Our Approved Medicines

Cystic fibrosis

KALYDECO® (ivacaftor)

ORKAMBI® (lumacaftor/ivacaftor)

SYMDEKO® (tezacaftor/ivacaftor and ivacaftor), known as SYMKEVI® in combination with ivacaftor in some countries

TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), known as KAFTRIO® in combination with ivacaftor in some countries

Sickle cell disease and transfusion-dependent beta thalassemia

CASGEVY™ (exagamglogene autotemcel)

The medicines listed above may not be approved by health authorities in all countries for the uses and populations mentioned.

Our Pipeline

Through our investment in R&D and both internal and external innovation, our pipeline programs span multiple serious diseases and therapeutic modalities.

For information on our pipeline programs, visit www.vrtx.com/our-science/pipeline.

- Cystic fibrosis
- Sickle cell disease
- Beta thalassemia
- Acute pain
- Neuropathic pain
- Type 1 diabetes
- APOL1-mediated kidney disease
- Autosomal dominant polycystic kidney disease
- Alpha-1 antitrypsin deficiency
- Duchenne muscular dystrophy
- Myotonic dystrophy type 1
- IgA nephropathy

Our Values

Our values are our bedrock and, combined with our culture, have enabled us to scale into multiple diseases and therapeutic modalities and deliver on our mission of creating transformative medicines for people with serious diseases. Our work is driven by these core values: Uncompromising Commitment to Patients, Innovation Is Our Lifeblood, Fearless Pursuit of Excellence, and “We” Wins.

Our ESG Commitment

Our culture of high ethical standards and ongoing environmental, social and governance (ESG) commitment, including inclusion, diversity and equity (ID&E), are core to Vertex’s ability to create and deliver transformative medicines for people with serious diseases.

For more information on our ESG efforts, check out our [2023 Corporate Responsibility Report](#), our [ID&E Fact Sheet](#), and visit www.vrtx.com/responsibility.

Visit www.vrtx.com to learn more and follow us on social media.

